FYR Diagnostics, Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

FYR Diagnostics, Inc. - overview

Established

2016

Location

Missoula, MT, US

Primary Industry

Biotechnology

About

Based in the US, FYR Diagnostics, Inc. engages in advancing diagnostic solutions. The company specializes in innovative approaches to enhance the capabilities of diagnostic testing for improved healthcare outcomes. Based in Missouri, US, and founded in 2016 by co-founders Braxton Norwood PhD, David Booth, Sarjubhai Patel, Thomas Rau, FYR Diagnostics, Inc.


focuses on developing advanced diagnostic solutions. In September 2025, FYR Diagnostics, Inc. raised USD 8 million in venture funding from investors Sontag Foundation and Yuvaan Tiwari Foundation, with participation from investor Two Bear Capital. The company specializes in a suite of innovative diagnostic solutions designed to advance healthcare testing.


Its core offerings include state-of-the-art diagnostic tools that enable healthcare professionals to improve patient outcomes efficiently. Additionally, FYR Diagnostics provides a range of analytical services and technologies that facilitate accurate disease detection and management, targeting healthcare providers across North America, Europe, and parts of Asia. The company's revenue model is structured around a combination of product sales and service agreements, creating a steady income stream from healthcare providers. Clients typically engage in annual contracts that grant them access to premium diagnostic services and ongoing support.


The company also generates revenue through the sale of proprietary diagnostic tools and services, which cater to the specific needs of healthcare facilities. Partnerships with medical institutions further enhance revenue opportunities, ensuring that their diagnostic solutions are widely adopted within the healthcare sector. FYR Diagnostics, Inc. plans to expand its product offerings by launching new diagnostic tools aimed at enhancing disease identification and management by the end of next year.


The company is also targeting expansion into European and Asian markets within the next two years, aiming to establish a stronger presence in those regions. The recent funding of USD 8. 00 mn will support these initiatives, enabling the company to invest in research and development as well as marketing efforts to reach broader audiences.


Current Investors

Two Bear Capital, Sontag Foundation, Yuvaan Tiwari Foundation

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Medical Software, Application Integration Software, Analytics & Performance Software

Website

www.fyr.bio

Verticals

Artificial Intelligence

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.